Corcept Therapeutics IncorporatedCORTNASDAQ
Loading
EBITDA Margin Over TimeContracting
Percentile Rank31
3Y CAGR-35.8%
5Y CAGR-27.3%
Year-over-Year Change
EBITDA as a percentage of revenue
3Y CAGR
-35.8%/yr
vs -5.6%/yr prior
5Y CAGR
-27.3%/yr
Recent deceleration
Acceleration
-30.2pp
Decelerating
Percentile
P31
Within normal range
vs 5Y Ago
0.2x
Contraction
Streak
6 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | 7.50% | -63.4% |
| 2024 | 20.49% | -8.8% |
| 2023 | 22.46% | -20.8% |
| 2022 | 28.34% | -18.9% |
| 2021 | 34.96% | -5.2% |
| 2020 | 36.86% | -0.7% |
| 2019 | 37.12% | +3.9% |
| 2018 | 35.71% | +7.4% |
| 2017 | 33.27% | +163.5% |
| 2016 | 12.62% | - |